Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitavastatin + Venetoclax in AML/CLL
NCT04512105Phase 1Completed
- Sponsor
- University of California, Irvine
- Start
- Dec 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pitavastatin in acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), sponsored by University of California, Irvine. Primary endpoints: Maximum Tolerated Dose at 2 years, Recommended Phase 2 Dose at 2 years and 3 more. Started Dec 2020; status: completed.
02
Drugs
pitavastatin
03
Conditions
acute myeloid leukemia (AML)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04512105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04512105.